Celgene Corporation announced that results from its ongoing phase III LIBERATE trial evaluating Otezla (apremilast), in patients with moderate to...
Celgene announced that results from its ongoing phase III LIBERATE trial evaluating Otezla (apremilast), an oral selective inhibitor of phosphodiesterase...
Objective: ESTEEM 1 evaluated efficacy/safety of apremilast at 30 mg twice a day for moderate to severe plaque psoriasis.
This study will test the clinical effectiveness and safety of apremilast compared with placebo as well as etanercept compared with...
Objectives: ESTEEM 2 evaluated the efficacy and safety of apremilast 30 mg twice daily for moderate-to-severe plaque psoriasis.
Objective: We evaluated the efficacy and safety of apremilast in palmoplantar psoriasis.
Background: Apremilast is an oral phosphodiesterase 4 inhibitor that has been approved as monotherapy for the treatment of moderate to severe chronic plaque psoriasis.
Objective: We sought to evaluate efficacy of apremilast in nail/scalp psoriasis in ESTEEM 1 and 2.
Bristol Myers Squibb announced that the FDA approved Sotyktu (deucravacitinib), a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Background: There are currently no independent data available comparing infliximab and etanercept for the treatment of psoriasis.